Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Research roundup: Massachusetts health reform; Role of race and insurance in kidney transplantation

Access to Care After Massachusetts' Health Care Reform: A Safety Net Hospital Patient Survey -- Policy analysts have long said that Massachusetts and its 2006 health reform law provide great insight into the federal health law and how its expansion of insurance coverage will play out.

3 Aug 2012

3D scanner can identify early foot deformity in RA patients

Researchers report that a digital 3D foot scanner can detect foot deformities in patients with rheumatoid arthritis, even before clinical signs are present.

2 Aug 2012

Australia's top medical researchers for 2012 announced

Finalists for one of Australia’s longest running and most prestigious awards for medical research were announced today. This year’s winner will join a list of alumni winners that includes many of the country’s most respected scientists.

31 Jul 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

Childhood deprivation linked to rheumatoid arthritis in adults

Adults with rheumatoid arthritis are more likely to have grown up in a low socioeconomic environment during childhood than those without RA, a large US case–control study shows.

30 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today that the European Commission has approved KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jul 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

The state can cut health care costs and reduce the number of medical-related lawsuits by requiring earlier notification of injuries as well as pretrial mediation, according to a recommendation Gov. John Kitzhaber issued Wednesday. The product of closed-door talks between representatives of interest groups including the Oregon Medical Association and the Oregon Trial Lawyers Association, Kitzhaber's recommendation now goes to a work group including lawmakers, a trial lawyer and doctor that begins public meetings next week.

27 Jul 2012

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Horizon Pharma, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved RAYOS (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD).

26 Jul 2012

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Protalex, Inc., a clinical stage biopharmaceutical company that is developing a class of drugs designed to treat a wide array of autoimmune and inflammatory diseases today announced preliminary findings from its recently completed Phase 1b randomized, multiple-dose, dose-escalation study.

26 Jul 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

Questcor second quarter net sales increase to $112.5 million

Questcor Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2012.

24 Jul 2012

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

SuppreMol GmbH, an autoimmune disease specialist, today announced a licensing agreement with the University Hospital of Regensburg to develop SM401, a humanized anti-IL-3 monoclonal antibody for early diagnosis and treatment of Rheumatoid Arthritis (RA). SuppreMol will advance preclinical development of SM401 for treatment of RA. Simultaneously, the Company will further validate a highly sensitive human IL-3 diagnostic assay for patient stratification.

24 Jul 2012

Researchers discover reason why breast cancer cells become drug resistant

Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

21 Jul 2012

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

A book containing misprints may cause annoyance for the reader, but typos in an individual's genetic blueprint (DNA) can mean serious disease or even death. The search for genetic correlates for the wide range of diseases plaguing humankind has inspired a wealth of research falling under the heading of genome-wide association studies (GWAS).

19 Jul 2012

Discrepancies between patients and physicians' views of RA disease activity

Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity.

18 Jul 2012

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Researchers from Austria have determined that patients with rheumatoid arthritis (RA) and their doctors differ on perception of RA disease activity. The study now available in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR) and published by Wiley, reports that RA patients cite joint pain as the reason for their perception of a change in their disease activity. Rheumatologists, however, stressed joint swelling as the major determinant for their perception of change in RA disease activity.

18 Jul 2012

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with systemic lupus erythematosus.

17 Jul 2012

Rheumatoid arthritis patients take-up cancer screening

Insurance records for rheumatoid arthritis patients in the USA indicate that patients are receiving their recommended cervical, breast, and colon cancer screening tests.

16 Jul 2012

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Research roundup: Massachusetts health reform; Role of race and insurance in kidney transplantation

3D scanner can identify early foot deformity in RA patients

Australia's top medical researchers for 2012 announced

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Childhood deprivation linked to rheumatoid arthritis in adults

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

EC approves Vertex's KALYDECO for treatment of cystic fibrosis

Anakinra can dramatically limit amount of brain damage in stroke patients

Roundup: Ore. Gov. suggests malpractice reform; Mass. Gov. proposes new scrutiny for health care providers; Texas has offered HPV vaccine since 2007

FDA approves Horizon Pharma's RAYOS to treat key IL-6 mediated diseases

Preliminary findings from Protalex's PRTX-100 Phase 1b study on active rheumatoid arthritis

Regeneron reports total revenues of $304 million for second quarter 2012

Questcor second quarter net sales increase to $112.5 million

Anti-IL-3 monoclonal antibodies to treat early stage Rheumatoid Arthritis in development

Researchers discover reason why breast cancer cells become drug resistant

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

Discrepancies between patients and physicians' views of RA disease activity

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Anthera announces final set of clinical data from blisibimod Phase 2b study on SLE

Rheumatoid arthritis patients take-up cancer screening

Innovation in neuroscience drug discovery - eBook eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Innovation in neuroscience drug discovery - eBook eBook

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in